Literature DB >> 18815387

Cognitive impairment and structural brain damage in benign multiple sclerosis.

M Rovaris1, G Riccitelli, E Judica, F Possa, D Caputo, A Ghezzi, A Bertolotto, R Capra, M Falautano, F Mattioli, V Martinelli, G Comi, M Filippi.   

Abstract

OBJECTIVE: Although in benign multiple sclerosis (BMS) locomotor disability is absent or only minimal, subclinical cognitive impairment seems to occur in many cases. Diffusion tensor (DT) MRI enables us to quantify the extent of "actual" tissue damage, which goes undetected when using conventional MRI. Against this background, we investigated the extent of structural brain damage underlying cognitive dysfunction in BMS, with the ultimate aim to move a first step toward a more reliable definition of this disease phenotype.
METHODS: Conventional and DT MRI scans of the brain were acquired from 62 BMS patients. Thirty-six secondary progressive multiple sclerosis (SPMS) patients and 19 healthy subjects served as controls. In BMS patients, neuropsychological tests exploring memory, attention, and frontal lobe functions were administered. Normalized brain volume (NBV), mean diffusivity (MD), and fractional anisotropy (FA) of the normal-appearing white matter (NAWM) and MD of the gray matter (GM) were computed.
RESULTS: Twelve BMS patients (19%) fulfilled predefined criteria for cognitive impairment. BMS patients had abnormal MD and FA values from both NAWM and GM. Whereas BMS patients without cognitive impairment had lower T2 LV (p = 0.03), higher NBV (p = 0.006), and lower average GM MD (p = 0.03) than SPMS patients, BMS patients with cognitive impairment did not significantly differ from SPMS patients for any MRI-derived metric.
CONCLUSIONS: In benign multiple sclerosis (BMS), cognitive dysfunction is associated with severe structural brain damage, which resembles that of patients with a much more disabling disease course. A reliable definition of BMS should, therefore, include the preservation of cognitive functioning as an additional requisite.

Entities:  

Mesh:

Year:  2008        PMID: 18815387     DOI: 10.1212/01.wnl.0000319694.14251.95

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  30 in total

Review 1.  Neuropsychological rehabilitation in adult multiple sclerosis.

Authors:  F Mattioli; C Stampatori; F Bellomi; R Capra; M Rocca; M Filippi
Journal:  Neurol Sci       Date:  2010-11       Impact factor: 3.307

2.  Additional efficacy endpoints from pivotal natalizumab trials in relapsing-remitting MS.

Authors:  Bianca Weinstock-Guttman; Steven L Galetta; Gavin Giovannoni; Eva Havrdova; Michael Hutchinson; Ludwig Kappos; Paul W O'Connor; J Theodore Phillips; Chris Polman; William H Stuart; Frances Lynn; Christophe Hotermans
Journal:  J Neurol       Date:  2011-10-19       Impact factor: 4.849

3.  Functional MR imaging correlates of neuropsychological impairment in primary-progressive multiple sclerosis.

Authors:  M A Rocca; G Riccitelli; M Rodegher; A Ceccarelli; A Falini; M Falautano; A Meani; G Comi; Massimo Filippi
Journal:  AJNR Am J Neuroradiol       Date:  2010-03-18       Impact factor: 3.825

4.  Improvement of neuropsychological function in cognitively impaired multiple sclerosis patients treated with natalizumab: a preliminary study.

Authors:  Keith R Edwards; William A Goodman; Carl Y Ma
Journal:  Int J MS Care       Date:  2012

5.  Visual pathway axonal loss in benign multiple sclerosis: a longitudinal study.

Authors:  Kristin M Galetta; Jennifer Graves; Lauren S Talman; Deacon J Lile; Elliot M Frohman; Peter A Calabresi; Steven L Galetta; Laura J Balcer
Journal:  J Neuroophthalmol       Date:  2012-06       Impact factor: 3.042

6.  MRI predictors of cognitive outcome in early multiple sclerosis.

Authors:  M S A Deloire; A Ruet; D Hamel; M Bonnet; V Dousset; B Brochet
Journal:  Neurology       Date:  2011-03-29       Impact factor: 9.910

7.  Multiple Sclerosis Severity Scale and whole-brain N-acetylaspartate concentration for patients' assessment.

Authors:  D J Rigotti; A Gass; L Achtnichts; M Inglese; J S Babb; Y Naegelin; J Hirsch; M Amann; L Kappos; O Gonen
Journal:  Mult Scler       Date:  2011-09-15       Impact factor: 6.312

8.  Evolving expectations around early management of multiple sclerosis.

Authors:  Ralf Gold; Jerry S Wolinsky; Maria Pia Amato; Giancarlo Comi
Journal:  Ther Adv Neurol Disord       Date:  2010-11       Impact factor: 6.570

Review 9.  The contribution of MRI in assessing cognitive impairment in multiple sclerosis.

Authors:  M Filippi; M A Rocca; R H B Benedict; J DeLuca; J J G Geurts; S A R B Rombouts; M Ron; G Comi
Journal:  Neurology       Date:  2010-12-07       Impact factor: 9.910

10.  Brain MRI lesion load at 1.5T and 3T versus clinical status in multiple sclerosis.

Authors:  James M Stankiewicz; Bonnie I Glanz; Brian C Healy; Ashish Arora; Mohit Neema; Ralph H B Benedict; Zachary D Guss; Shahamat Tauhid; Guy J Buckle; Maria K Houtchens; Samia J Khoury; Howard L Weiner; Charles R G Guttmann; Rohit Bakshi
Journal:  J Neuroimaging       Date:  2011-04       Impact factor: 2.486

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.